Stock

Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

26/04/2025
admin


Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer#Pfizer039s #Sasanlimab #Combination #Significantly #Improves #EventFree #Survival #BCGNaÃve #HighRisk #NonMuscle #Invasive #Bladder #Cancer